Subsequently, the difference of expression of six candidate tissue biomarkers, including the Hippo pathway proteins (YAP1 and MOB4A) with steroid receptors (AR, GR, PR, and ERα), which were known to play a key role in PCa progression and resistance [26–28], among the three groups with different neoadjuvant treatments by the IHC analyses was investigated. This evidence concerns the gene MOB1B and posterior cortical atrophy.